ECONOMIC BURDEN OF PATIENTS WITH ALK+ MUTATION NON-SMALL CELL LUNG CANCER AFTER TREATMENT WITH CRIZOTINIB- A CANADIAN RETROSPECTIVE OBSERVATIONAL STUDY
Author(s)
Kayaniyil S1, Wilson J2, Hurry M3, Koch C3, Zhang J4, Liu G5
1ICON plc, Toronto, ON, Canada, 2ICON plc, Vancouver, ON, Canada, 3Novartis Pharmaceuticals Inc., Dorval, QC, Canada, 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 5Princess Margaret Cancer Centre, Toronto, ON, Canada
OBJECTIVES: Non-small cell lung cancer (NSCLC) accounts for 85-90% of all lung cancers. Anaplastic lymphoma kinase (ALK) gene rearrangement mutations are found in 4-7% of NSCLC tumours. Crizotinib is indicated for treatment of patients with ALK-positive (ALK+) advanced or metastatic NSCLC. However, patients eventually progress/develop resistance over time. There is limited evidence on the economic burden among Canadian ALK+ NSCLC patients who discontinue crizotinib. METHODS: A chart review study was conducted to assess treatment patterns, resource utilization and associated costs among patients with locally advanced or metastatic ALK+ NSCLC, diagnosed 2010-2015, who were intolerant to or progressed on crizotinib treatment. Data were collected from medical charts from six Canadian oncology centres. Cost estimates were calculated using a ‘bottom-up’ approach, where frequency of utilization, retrieved by type and frequency, was multiplied by each resource unit cost. Costing was performed with the public payer’s perspective, and as ceritinib was approved in March 2015, associated costs were excluded. RESULTS: A total of 97 charts were included, with 49 crizotinib-failures, 9 crizotinib-naive and 39 ongoing crizotinib treatment. Among those who failed crizotinib treatment, mean age at diagnosis was 53 years, with 53% female, 53% Caucasian, and 67% non-smokers. Treatment patterns post crizotinib in any line of treatment was ceritinib (43%), targeted therapy (6%), platinum doublets (23%), single agent chemotherapy (23%)and no further systemic treatment (41%); 35% and 33% of patients received concurrent palliative care and/or radiotherapy, respectively. Median overall survival in patients who received non-ceritinib treatment was 1.7 months. Total mean cost for completed systemic treatment post-crizotinib was $16,473/patient, excluding ceritinib costs. Other costs included palliative care and radiotherapy. Mean monthly cost for resource use was $4,382/patient. CONCLUSIONS: Treatment patterns post-crizotinib were heterogeneous. Estimated economic burden in patients who received active treatment remains significant despite their poor prognosis.
Conference/Value in Health Info
2015-11, ISPOR Europe 2015, Milan, Italy
Value in Health, Vol. 18, No. 7 (November 2015)
Code
PCN126
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Oncology